Cargando…
The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes
Immune checkpoint inhibitors (ICIs) cause a variety of inflammatory eruptions. The understanding of ICI-induced inflammatory eruptions with detailed histopathological findings is not adequate, particularly in Asian populations. In this study, we retrospectively reviewed 51 patients who were histopat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918541/ https://www.ncbi.nlm.nih.gov/pubmed/33673164 http://dx.doi.org/10.3390/jcm10040728 |
_version_ | 1783657946400423936 |
---|---|
author | Hashimoto, Hiroki Ito, Takamichi Ichiki, Toshio Yamada, Yuichi Oda, Yoshinao Furue, Masutaka |
author_facet | Hashimoto, Hiroki Ito, Takamichi Ichiki, Toshio Yamada, Yuichi Oda, Yoshinao Furue, Masutaka |
author_sort | Hashimoto, Hiroki |
collection | PubMed |
description | Immune checkpoint inhibitors (ICIs) cause a variety of inflammatory eruptions. The understanding of ICI-induced inflammatory eruptions with detailed histopathological findings is not adequate, particularly in Asian populations. In this study, we retrospectively reviewed 51 patients who were histopathologically diagnosed with cutaneous immune-related adverse events (irAEs) following ICI therapy between 2014 and 2020 at the Department of Dermatology of Kyushu University Hospital. Of the 51 patients (30 men, 21 women), maculopapular rash (38/51, 74.5%), erythema multiforme (2/51, 3.9%), lichenoid reaction (3/51, 5.9%), psoriasiform reaction (3/51, 5.9%), bullous pemphigoid (3/51, 5.9%), scleroderma-like reaction (1/51, 2.0%), and Stevens–Johnson syndrome (1/51, 2.0%) were observed. The clinical and histopathological findings of these eruptions were equivalent to typical cases of common drug eruptions. The onset of maculopapular rash was relatively early (more than half of events occurred within 1 month), whereas lichenoid reactions and autoimmune diseases occurred relatively late (4–8 months). With appropriate treatment and/or interruption of ICIs, most rashes improved (50/51, 98.0%). The ICI-induced inflammatory eruptions shared similar clinical and histopathological features with classical inflammatory eruptions, but a variety of inflammatory eruptions may occur with different degrees of severity. Dermatologists play an important role in providing specialized care for cutaneous irAEs. |
format | Online Article Text |
id | pubmed-7918541 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79185412021-03-02 The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes Hashimoto, Hiroki Ito, Takamichi Ichiki, Toshio Yamada, Yuichi Oda, Yoshinao Furue, Masutaka J Clin Med Article Immune checkpoint inhibitors (ICIs) cause a variety of inflammatory eruptions. The understanding of ICI-induced inflammatory eruptions with detailed histopathological findings is not adequate, particularly in Asian populations. In this study, we retrospectively reviewed 51 patients who were histopathologically diagnosed with cutaneous immune-related adverse events (irAEs) following ICI therapy between 2014 and 2020 at the Department of Dermatology of Kyushu University Hospital. Of the 51 patients (30 men, 21 women), maculopapular rash (38/51, 74.5%), erythema multiforme (2/51, 3.9%), lichenoid reaction (3/51, 5.9%), psoriasiform reaction (3/51, 5.9%), bullous pemphigoid (3/51, 5.9%), scleroderma-like reaction (1/51, 2.0%), and Stevens–Johnson syndrome (1/51, 2.0%) were observed. The clinical and histopathological findings of these eruptions were equivalent to typical cases of common drug eruptions. The onset of maculopapular rash was relatively early (more than half of events occurred within 1 month), whereas lichenoid reactions and autoimmune diseases occurred relatively late (4–8 months). With appropriate treatment and/or interruption of ICIs, most rashes improved (50/51, 98.0%). The ICI-induced inflammatory eruptions shared similar clinical and histopathological features with classical inflammatory eruptions, but a variety of inflammatory eruptions may occur with different degrees of severity. Dermatologists play an important role in providing specialized care for cutaneous irAEs. MDPI 2021-02-12 /pmc/articles/PMC7918541/ /pubmed/33673164 http://dx.doi.org/10.3390/jcm10040728 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hashimoto, Hiroki Ito, Takamichi Ichiki, Toshio Yamada, Yuichi Oda, Yoshinao Furue, Masutaka The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes |
title | The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes |
title_full | The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes |
title_fullStr | The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes |
title_full_unstemmed | The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes |
title_short | The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes |
title_sort | clinical and histopathological features of cutaneous immune-related adverse events and their outcomes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918541/ https://www.ncbi.nlm.nih.gov/pubmed/33673164 http://dx.doi.org/10.3390/jcm10040728 |
work_keys_str_mv | AT hashimotohiroki theclinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes AT itotakamichi theclinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes AT ichikitoshio theclinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes AT yamadayuichi theclinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes AT odayoshinao theclinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes AT furuemasutaka theclinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes AT hashimotohiroki clinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes AT itotakamichi clinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes AT ichikitoshio clinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes AT yamadayuichi clinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes AT odayoshinao clinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes AT furuemasutaka clinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes |